Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer

Oncology Letters

Volumn 3, Issue 3, 2012, Pages 530-534

  Rein, Daniel T ^a   Volkmer, Anne Kathrin ^a   Jens, Volkmer ^a   Beyer, Ines M ^a,b   Wolfgang, Janni ^a   Fleisch, Markus C ^a   Welter, Anne Kathrin ^a   Dirk, Bauerschlag ^c   Thomas, SCHÖNDORF ^d   Martina, Breidenbach ^c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d Institute for Clinical Research and Development   (Germany)

Author keywords

Administration route; Advanced ovarian cancer; Murine model; Palliation; Single doses

Indexed keywords

BEVACIZUMAB; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; BODY SURFACE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; SINGLE DRUG DOSE; SURVIVAL RATE; SYSTEMIC THERAPY;

EID: 84855681894     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.553     Document Type: Article

References (23)

1. Eitan R, Levine DA, Abu-Rustum N, et al: The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma. Cancer 103: 1397-1401, 2005.
2. Sherer DM, Eliakim R and Abulafia O: The role of angiogenesis in the accumulation of peritoneal fluid in benign conditions and the development of malignant ascites in the female. Gynecol Obstet Invest 50: 217-224, 2000.
3. Markman M: Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 4: 277-283, 2003.
4. Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C and Atanackovic D: Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist 14: 1242-1251, 2009.
5. Aslam N and Marino CR: Malignant ascites: new concepts in pathophysiology, diagnosis, and management. Arch Intern Med 161: 2733-2737, 2001.
6. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS and Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985, 1983.
7. Huynh H, Teo CC and Soo KC: Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Mol Cancer Ther 6: 2959-2966, 2007.
8. Sack U, Hoffmann M, Zhao XJ, et al: Vascular endothelial growth factor in pleural effusions of different origin. Eur Respir J 25: 600-604, 2005.
9. Numnum TM, Rocconi RP, Whitworth J and Barnes MN: The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 102: 425-428, 2006.
10. Cannistra SA, Matulonis UA, Penson RT, et al: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25: 5180-5186, 2007.
11. Simpkins F, Belinson JL and Rose PG: Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol 107: 118-123, 2007.
12. Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Farley JH and Rose GS: Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol 111: 530-532, 2008.
13. Burger RA, Sill MW, Monk BJ, Greer BE and Sorosky JI: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 5165-5171, 2007.
14. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB and Ellis LM: Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 6: 373-378, 1999.
15. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611, 2004.
16. Rein DT, Breidenbach M, Nettelbeck DM, et al: Evaluation of tissue-specific promoters in carcinomas of the cervix uteri. J Gene Med 6: 1281-1289, 2004.
17. Gerber HP and Ferrara N: Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65: 671-680, 2005.
18. Jain RK, Duda DG, Clark JW and Loeffler JS: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3: 24-40, 2006.
19. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T and Jaffe RB: Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 161: 1917-1924, 2002.
20. Mabuchi S, Terai Y, Morishige K, et al: Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin Cancer Res 14: 7781-7789, 2008.
21. Shah DK, Shin BS, Veith J, Toth K, Bernacki RJ and Balthasar JP: Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy. J Pharmacol Exp Ther 329: 580-591, 2009.
22. Davies S, Dai D, Pickett G, Thiel KW, Korovkina VP and Leslie KK: Effects of bevacizumab in mouse model of endometrial cancer: Defining the molecular basis for resistance. Oncol Rep 25: 855-862.
23. Shah DK, Veith J, Bernacki RJ and Balthasar JP: Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer. Cancer Chemother Pharmacol 68: 951-958, 2011.